Contact
searchSearch
HMP Global

February 2012 - FRMC

Vemurafenib Accelerates Secondary Skin Cancer in Some Patients
02/22/2012
Eileen Koutnik-Fotopoulos
Although vemurafenib improves outcomes in patients with advanced melanoma that harbors a BRAF gene mutation, the drug also accelerates the development of squamous-cell carcinomas and keratoacanthomas in some patients. Results that show a skin...
Although vemurafenib improves outcomes in patients with advanced melanoma that harbors a BRAF gene mutation, the drug also accelerates the development of squamous-cell carcinomas and keratoacanthomas in some patients. Results that show a skin...
Although vemurafenib improves...
02/22/2012
First Report Managed Care
News Connection
Genital Herpes Vaccine Only Protects against One Strain of Virus
02/22/2012
Eileen Koutnik-Fotopoulos
A vaccine for genital herpes was effective in protecting some women from genital disease and infection from herpes simplex type 1 but not from type 2.
A vaccine for genital herpes was effective in protecting some women from genital disease and infection from herpes simplex type 1 but not from type 2.
A vaccine for genital herpes was...
02/22/2012
First Report Managed Care
HPV Vaccination among Teens
02/22/2012
Kevin L. Carter
Human papillomavirus (HPV) is the most prevalent sexually transmitted infection (STI) in the United States. HPV has a prevalence of 29.5% in sexually experienced girls 14 to 19 years of age. Sequelae of HPV infection may include genital...
Human papillomavirus (HPV) is the most prevalent sexually transmitted infection (STI) in the United States. HPV has a prevalence of 29.5% in sexually experienced girls 14 to 19 years of age. Sequelae of HPV infection may include genital...
Human papillomavirus (HPV) is...
02/22/2012
First Report Managed Care
Treating Osteoporosis in Postmenopausal Women
02/22/2012
Tim Casey
New Orleans—According to an analysis of clinical trials, bazedoxifene is effective as a second-line therapy for postmenopausal women who have osteoporosis, although the drug is not cost-effective compared with raloxifene. Bazedoxifene and...
New Orleans—According to an analysis of clinical trials, bazedoxifene is effective as a second-line therapy for postmenopausal women who have osteoporosis, although the drug is not cost-effective compared with raloxifene. Bazedoxifene and...
New Orleans—According to an...
02/22/2012
First Report Managed Care
Cost Comparison of Fulvestrant Regimens
02/22/2012
Eileen Koutnik-Fotopoulos
A study comparing the cost of fulvestrant found that 250 mg appears to be a cost-effective option in treating postmenopausal women with breast cancer.
A study comparing the cost of fulvestrant found that 250 mg appears to be a cost-effective option in treating postmenopausal women with breast cancer.
A study comparing the cost of...
02/22/2012
First Report Managed Care
Length of Hospital Stay Associated with Dabigatran and Warfarin
02/22/2012
Tim Casey
New Orleans—A retrospective cohort study found that patients with atrial fibrillation (AF) who took dabigatran did not have a significant reduction in length of stay in a hospital compared with those who took warfarin. However, the authors...
New Orleans—A retrospective cohort study found that patients with atrial fibrillation (AF) who took dabigatran did not have a significant reduction in length of stay in a hospital compared with those who took warfarin. However, the authors...
New Orleans—A retrospective...
02/22/2012
First Report Managed Care
Cost-Effectiveness and Survival of HRPC Treatments
02/22/2012
Eileen Koutnik-Fotopoulos
To determine survival benefits for patients with hormone-refractory prostate cancer, researchers looked at treating HRPC with sipuleucel-T and docetaxel.
To determine survival benefits for patients with hormone-refractory prostate cancer, researchers looked at treating HRPC with sipuleucel-T and docetaxel.
To determine survival benefits...
02/22/2012
First Report Managed Care
Conference Insider
Serious Infections in Patients with Autoimmune Diseases
02/22/2012
Mary Beth Nierengarten
Chicago—The risk of serious infection was not significantly increased in patients with autoimmune diseases initiating treatment with tumor necrosis factor (TNF) antagonists compared with those treated with nonbiologic disease regimens, even...
Chicago—The risk of serious infection was not significantly increased in patients with autoimmune diseases initiating treatment with tumor necrosis factor (TNF) antagonists compared with those treated with nonbiologic disease regimens, even...
Chicago—The risk of serious...
02/22/2012
First Report Managed Care
Conference Insider
Anti-TNF Therapy and Solid Cancer Risk
02/22/2012
Mary Beth Nierengarten
Chicago—Patients treated with anti–tumor necrosis factor (TNF) therapy for rheumatoid arthritis (RA) are not at increased risk of solid cancers compared with patients receiving nonbiologic disease-modifying antirheumatic drugs (DMARDs),...
Chicago—Patients treated with anti–tumor necrosis factor (TNF) therapy for rheumatoid arthritis (RA) are not at increased risk of solid cancers compared with patients receiving nonbiologic disease-modifying antirheumatic drugs (DMARDs),...
Chicago—Patients treated with...
02/22/2012
First Report Managed Care
TNF Antagonists and Cardiovascular Disease Risk
02/22/2012
Mary Beth Nierengarten
Chicago—Data from a large epidemiologic study presented at the ACR meeting suggest a trend toward reduced cardiovascular disease (CVD) risk among patients with rheumatoid arthritis (RA) during the first 6 months of initiating treatment with...
Chicago—Data from a large epidemiologic study presented at the ACR meeting suggest a trend toward reduced cardiovascular disease (CVD) risk among patients with rheumatoid arthritis (RA) during the first 6 months of initiating treatment with...
Chicago—Data from a large...
02/22/2012
First Report Managed Care
Subcutaneous versus Intravenous Abatacept in Rheumatoid Arthritis
02/22/2012
Mary Beth Nierengarten
Chicago—The efficacy and safety of subcutaneous (SC) abatacept to treat rheumatoid arthritis (RA) was maintained over 24 months, according to investigators of a recent open-label long-term extension study that looked at 24-month follow-up...
Chicago—The efficacy and safety of subcutaneous (SC) abatacept to treat rheumatoid arthritis (RA) was maintained over 24 months, according to investigators of a recent open-label long-term extension study that looked at 24-month follow-up...
Chicago—The efficacy and safety...
02/22/2012
First Report Managed Care
3-Year Analysis of Patients Treated with Golimumab
02/22/2012
Mary Beth Nierengarten
Chicago—In patients with anemia of inflammation due to chronic rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PSA), treatment with golimumab was associated with greater improvements in hemoglobin at 6 months...
Chicago—In patients with anemia of inflammation due to chronic rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PSA), treatment with golimumab was associated with greater improvements in hemoglobin at 6 months...
Chicago—In patients with anemia...
02/22/2012
First Report Managed Care
Conference Insider
Earlier Onset Knee Osteoarthritis Impacts Healthcare System
02/22/2012
Mary Beth Nierengarten
Chicago—New data highlight the increasing number of people in the United States newly diagnosed with knee osteoarthritis (OA), particularly younger people, and the additional burden it is estimated this will place on the US healthcare system...
Chicago—New data highlight the increasing number of people in the United States newly diagnosed with knee osteoarthritis (OA), particularly younger people, and the additional burden it is estimated this will place on the US healthcare system...
Chicago—New data highlight the...
02/22/2012
First Report Managed Care
ACR Recommendations for Treating Rheumatoid Arthritis
02/22/2012
Mary Beth Nierengarten
Chicago—New recommendations for the treatment of rheumatoid arthritis (RA) are near completion and will provide evidence-based recommendations on a number of issues related to the use of biologics and traditional disease-modifying...
Chicago—New recommendations for the treatment of rheumatoid arthritis (RA) are near completion and will provide evidence-based recommendations on a number of issues related to the use of biologics and traditional disease-modifying...
Chicago—New recommendations for...
02/22/2012
First Report Managed Care
Staff Morale Is Correlated with Perceived PCMH Characteristics
02/21/2012
Jill Sederstorm
Healthcare providers and staff who perceived more patient-centered medical home (PCMH) characteristics at their workplace were more likely to report higher morale, according to the results of a recent study. The findings from the study were...
Healthcare providers and staff who perceived more patient-centered medical home (PCMH) characteristics at their workplace were more likely to report higher morale, according to the results of a recent study. The findings from the study were...
Healthcare providers and staff...
02/21/2012
First Report Managed Care
AMCP Comments on Proposed CMS Changes to Part D Reporting Requirements
02/21/2012
Mary Beth Nierengarten
Future changes to Part D Reporting Requirements proposed by the Centers for Medicare & Medicaid Services (CMS) for contract year 2013 may pose new challenges to Part D plan sponsors if enacted. Responding to a request by CMS for comments on...
Future changes to Part D Reporting Requirements proposed by the Centers for Medicare & Medicaid Services (CMS) for contract year 2013 may pose new challenges to Part D plan sponsors if enacted. Responding to a request by CMS for comments on...
Future changes to Part D...
02/21/2012
First Report Managed Care
Alternative Benefit Design for Medicare
02/21/2012
Jill Sederstorm
Restructuring the Medicare benefit design and placing a limit on beneficiary cost-sharing for Medicare-covered services in 2013 could lead to savings for Medicare and a minority of beneficiaries with high medical spending, but it could also...
Restructuring the Medicare benefit design and placing a limit on beneficiary cost-sharing for Medicare-covered services in 2013 could lead to savings for Medicare and a minority of beneficiaries with high medical spending, but it could also...
Restructuring the Medicare...
02/21/2012
First Report Managed Care
Implementing the Summary of Benefits and Coverage Provision of the ACA
02/21/2012
Tori Socha
The Patient Protection and Affordable Care Act of 2010 (ACA) includes a provision requiring private individual and group health plans to provide all applicants and enrollees with a uniform summary of benefits and coverage (SBC). The provision...
The Patient Protection and Affordable Care Act of 2010 (ACA) includes a provision requiring private individual and group health plans to provide all applicants and enrollees with a uniform summary of benefits and coverage (SBC). The provision...
The Patient Protection and...
02/21/2012
First Report Managed Care
Post–Myocardial-Infarction Medications with No Copayments
02/21/2012
Tori Socha
Patients in the United States with acute myocardial infarction are most often prescribed a medication regimen at discharge from the hospital. However, gaps in care can occur following discharge, due mainly to either a failure to fill the...
Patients in the United States with acute myocardial infarction are most often prescribed a medication regimen at discharge from the hospital. However, gaps in care can occur following discharge, due mainly to either a failure to fill the...
Patients in the United States...
02/21/2012
First Report Managed Care
Risk of Diabetes Correlates with Duration of Obesity
02/21/2012
Eileen Koutnik-Fotopoulos
The degree and duration of obesity, expressed as excess body mass index (BMI)-years, increases the risk of developing type 2 diabetes more than BMI alone, but race and young age also are risk factors, according to the results of a...
The degree and duration of obesity, expressed as excess body mass index (BMI)-years, increases the risk of developing type 2 diabetes more than BMI alone, but race and young age also are risk factors, according to the results of a...
The degree and duration of...
02/21/2012
First Report Managed Care
Race Influences Risk of Emergency Diverticulitis Surgery
02/21/2012
Kristina Woodworth
A study published in Archives of Surgery [2011;146(11):1272-1276] has reported that black patients were more likely to undergo emergency surgery for diverticulitis and had a higher in-hospital mortality risk compared with white counterparts.
A study published in Archives of Surgery [2011;146(11):1272-1276] has reported that black patients were more likely to undergo emergency surgery for diverticulitis and had a higher in-hospital mortality risk compared with white counterparts.
A study published in Archives of...
02/21/2012
First Report Managed Care
Routine Use of Aspirin for Primary Prevention of Cardiovascular Events
02/21/2012
Mary Mihalovic
The use of aspirin for primary prevention of cardiovascular events was not shown to be beneficial for preventing fatal myocardial infarction (MI), stroke, or death related to cardiovascular disease (CVD) or cancer, according to results of a...
The use of aspirin for primary prevention of cardiovascular events was not shown to be beneficial for preventing fatal myocardial infarction (MI), stroke, or death related to cardiovascular disease (CVD) or cancer, according to results of a...
The use of aspirin for primary...
02/21/2012
First Report Managed Care
Prophylaxis with Apixaban for Acutely Ill Patients
02/21/2012
Jill Sederstorm
A double-blind study evaluating the safety and efficacy of extended prophylaxis with apixaban for venous thromboembolism in acutely ill patients found that the extended treatment was not superior to short-term prophylaxis with enoxaparin;...
A double-blind study evaluating the safety and efficacy of extended prophylaxis with apixaban for venous thromboembolism in acutely ill patients found that the extended treatment was not superior to short-term prophylaxis with enoxaparin;...
A double-blind study evaluating...
02/21/2012
First Report Managed Care
News Connection
Bivalirudin Compared with Abciximab plus Heparin for Non-STEMI
02/21/2012
Tori Socha
High-risk patients who have an acute coronary syndrome are often treated with an invasive strategy of coronary angiography. Identifying the most appropriate adjunctive antithrombotic therapy prior to, during, and following percutaneous...
High-risk patients who have an acute coronary syndrome are often treated with an invasive strategy of coronary angiography. Identifying the most appropriate adjunctive antithrombotic therapy prior to, during, and following percutaneous...
High-risk patients who have an...
02/21/2012
First Report Managed Care
ABVD Chemotherapy without Radiation Associated with Increased Survival in Hodgkin’s Lymphoma
02/21/2012
Kristina Woodworth
A randomized study has found that doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy was associated with a higher rate of 12-year overall survival than subtotal nodal radiation therapy, with or without ABVD, in patients...
A randomized study has found that doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy was associated with a higher rate of 12-year overall survival than subtotal nodal radiation therapy, with or without ABVD, in patients...
A randomized study has found...
02/21/2012
First Report Managed Care
SBP and Risk of Recurrent Stroke
02/21/2012
Tori Socha
In persons with a prior stroke, national guidelines suggest maintaining a normal blood pressure (BP), defined as systolic BP (SBP) of <120 mm Hg and a diastolic BP of <80 mm Hg. According to researchers, data specifically addressing the...
In persons with a prior stroke, national guidelines suggest maintaining a normal blood pressure (BP), defined as systolic BP (SBP) of <120 mm Hg and a diastolic BP of <80 mm Hg. According to researchers, data specifically addressing the...
In persons with a prior stroke,...
02/21/2012
First Report Managed Care
Awareness of Glaucoma Lacking
02/21/2012
Tim Casey
Of the 60 million people worldwide and 2.2 million in the United States who have glaucoma, approximately half do not know they suffer from the group of diseases, according to the Glaucoma Research Foundation (GRF). To publicize glaucoma, the...
Of the 60 million people worldwide and 2.2 million in the United States who have glaucoma, approximately half do not know they suffer from the group of diseases, according to the Glaucoma Research Foundation (GRF). To publicize glaucoma, the...
Of the 60 million people...
02/21/2012
First Report Managed Care
News Connection
Rivaroxaban Treatment for Patients with a Recent Acute Coronary Syndrome
02/21/2012
Tori Socha
Standard medical therapy following an acute coronary syndrome includes long-term antiplatelet therapy with aspirin and an adenosine diphosphate receptor inhibitor. Despite this therapy, patients remain at risk for recurrent cardiovascular...
Standard medical therapy following an acute coronary syndrome includes long-term antiplatelet therapy with aspirin and an adenosine diphosphate receptor inhibitor. Despite this therapy, patients remain at risk for recurrent cardiovascular...
Standard medical therapy...
02/21/2012
First Report Managed Care
Supreme Court to Address Healthcare Reform Law
02/21/2012
Jill Sederstorm
The Supreme Court will soon weigh in on the healthcare reform law and its constitutionality by reviewing 2 key provisions of the Patient Protection and Affordable Care Act (ACA): the individual mandate and the Medicaid expansion. A new brief...
The Supreme Court will soon weigh in on the healthcare reform law and its constitutionality by reviewing 2 key provisions of the Patient Protection and Affordable Care Act (ACA): the individual mandate and the Medicaid expansion. A new brief...
The Supreme Court will soon...
02/21/2012
First Report Managed Care
Lawmakers Introduce Bills to Reduce Drug Costs
02/21/2012
Tim Casey
With prescription drug prices rising and governments facing dire financial situations, elected officials have proposed legislation that would lower drug prices.
With prescription drug prices rising and governments facing dire financial situations, elected officials have proposed legislation that would lower drug prices.
With prescription drug prices...
02/21/2012
First Report Managed Care
Pharmaceutical Companies Losing Patent Exclusivities
02/21/2012
Tim Casey
Since the US Food and Drug Administration approved Lipitor (atorvastatin) in the late 1990s, Pfizer, Inc, could rely on the cholesterol-lowering drug to generate billions in revenue. The product became the best-selling drug in history,...
Since the US Food and Drug Administration approved Lipitor (atorvastatin) in the late 1990s, Pfizer, Inc, could rely on the cholesterol-lowering drug to generate billions in revenue. The product became the best-selling drug in history,...
Since the US Food and Drug...
02/21/2012
First Report Managed Care

Pipeline Projections

PIPELINE PROJECTIONS
Emerging Therapies Reshaping Atopic Dermatitis Care
03/26/2026
Roy Moore
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly...
03/26/2026
First Report Managed Care
Pipe
Pipeline Projections
Emerging Migraine Treatments Challenge a Mature Market
11/20/2025
Roy Moore
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market...
11/20/2025
First Report Managed Care
Pipeline Projections
Pipeline Projections
Redefining Asthma Management With Emerging Anti-Inflammatories
10/01/2025
Roy Moore
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access...
10/01/2025
First Report Managed Care
Pipeline Projections
The Shift in MS Care as Biologics and BTK Inhibitors Advance
07/25/2025
Roy Moore
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline...
07/25/2025
First Report Managed Care
Pipeline Projections
How Biosimilars Are Shaping RA Treatment and Reimbursement Strategies
04/29/2025
Roy Moore
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline...
04/29/2025
First Report Managed Care

Subscribe to receive the latest updates in managed care!

First Report Managed Care Newsletter

Behind the Bill

Behind the Bill
HHS Hits Reset on 340B Rebate Model After Court Setbacks
02/11/2026
Juliet Gallagher
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and...
02/11/2026
First Report Managed Care
Behind the Bill
Funding Package Extends Medicare Telehealth, Enacts PBM Reforms, and Updates Hospital Oversight
02/05/2026
Juliet Gallagher
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President...
02/05/2026
First Report Managed Care
Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care

February 2012 Volume 9 Issue 2

View Issue Archive
Editorial Correspondence

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use